Evaluation of a Daily Disposable Silicone Hydrogel Multifocal Contact Lens in Myopes and Hyperopes

NCT05222880 | Completed Results FDA Device

• 1 other identifier: CR-6477
• Study Type: interventional
• Target: 140
• Locations: 1 country
• Sites: 12

Brief Summary

This is a single-masked, single-arm, dispensing clinical trial that will evaluate vision, eye health and fit acceptance.

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (4)

• Binocular logMAR Visual Acuity

  Binocular visual acuity was measured on a logMAR (Logarithm of Minimal Angle of Resolution) scale under high luminance high contrast condition. At distance (4 meters), VA is assessed using ETDRS (Early Treatment Diabetic Retinopathy Study) charts; while near (40 cm) and intermediate (64 cm) assessments were made using reduced Guillon-Poling charts. Letter-by-letter results calculated the visual performance score for each chart read. LogMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.

  1-Week Follow-up

• CLUE Vision Score

  Subjective vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The average CLUE vision score for each sphere stratum (Hyperope and Myope) was reported.

  1-Week Follow-up

• Proportion of Eyes With Unacceptable Lens Fitting

  Contact lens fitting acceptance was assessed for each subject eye using a biomicroscope post lens insertion, the 1-week follow-up and any unscheduled visits. Lens fit was a binary variable where acceptable lens fit=1 and unacceptable lens fit=0. The proportion of eyes with unacceptable lens fit was reported.

  Up to 1-Week Follow-up

• Proportion of Eyes With Grade 3 or Higher Slit Lamp Findings

  Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). This was performed on each subject eye at every study visit (baseline, unscheduled visits and 1-week follow-up). The data was then dichotomized into two groups. Those with grade 3 or higher and those with grade 2 or lower. The proportion of eyes with SLF with grade 3 or higher was reported.

  Up to 1-Week Follow-up

Secondary Outcomes (4)

• CLUE Vision Score

  1-Week Follow-up

• CLUE Comfort Score

  1-Week Follow-up

• CLUE Handling Score

  1-Week Follow-up

• Proportion of Subject Achieving Optimal Lens Pair in 4 Lenses or Less

  Up to 1-Week Follow-up

Study Arms (1)

TEST Lens

EXPERIMENTAL

Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.

Device: JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3

Interventions

JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3 DEVICE

TEST Lens

TEST Lens

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:
• Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
• Appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Be at least 40 years of age and not greater than 70 years of age at the time of consent.
• Own a wearable pair of spectacles if required for their distance vision.
• Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 1 month or more duration).
• Either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
• The subject's distance spherical equivalent refraction (vertex corrected if ≥-4.25 D) must be in the range of -1.25 D to -5.75 D or +0.75 D to +3.25 D in each eye.
• The subject's refractive cylinder must be ≤0.75 D in each eye.
• The subject's ADD power must be in the range of +0.75 D to +2.50 D.
• The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.

You may not qualify if:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:
• Be currently pregnant or lactating.
• Have any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
• Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens- Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
• Have any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal surgery, etc.).
• Have a history of amblyopia, strabismus or binocular vision abnormality.
• Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids. See section 9.1 for further examples.
• Use of any ocular medication, with the exception of rewetting drops.
• Have a history of herpetic keratitis.
• Have a history of irregular cornea.
• Have a history of pathological dry eye.
• Have Participated in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
• Be and employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
• Have any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein.
• Have clinically significant (Grade 2 or greater) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (12)

Vue Optical Boutique

Jacksonville, Florida, 32205, United States

Location

Stam & Associates Eye Care

Jacksonville, Florida, 32256, United States

Location

Maitland Vision Center - North Orlando Ave

Maitland, Florida, 32751, United States

Location

Tallahassee Eye Center

Tallahassee, Florida, 32308, United States

Location

Kannarr Eye Care

Pittsburg, Kansas, 66762, United States

Location

Birmingham Vision Care

Bloomfield Hills, Michigan, 48601, United States

Location

Eye Associates of New York

Manhattan, New York, 10022, United States

Location

Sacco Eye Group

Vestal, New York, 13850, United States

Location

Dr. David W. Ferris & Associates

Warwick, Rhode Island, 02888, United States

Location

Optometry Group, LLC

Memphis, Tennessee, 38111, United States

Location

Vision Optique

Houston, Texas, 77005, United States

Location

Tyler Eye Associates

Tyler, Texas, 75703, United States

Location

Results Point of Contact

• Title: Thomas R. Karkkainen
• Organization: Johnson & Johnson Vision Care, Inc. (JJVC)

TKarkkai@its.jnj.com

(904)254-0152

Study Officials

• Johnson & Johnson Vision Care, Inc. Clinical Trial

  Johnson & Johnson Vision Care, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2022
• First Posted: February 3, 2022
• Study Start: January 6, 2022
• Primary Completion: February 28, 2022
• Study Completion: February 28, 2022
• Last Updated: April 13, 2023
• Results First Posted: April 13, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will share

Locations

US (12)